Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSCs for Idiopathic Parkinson's Disease
NCT02611167Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Nov 2017
- Primary completion
- Sep 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic bone marrow-derived mesenchymal stromal cells in Parkinson's disease (PD) (4 arms), sponsored by UTHealth Houston. Primary endpoint: Safety of allogeneic MSC therapy at 52 weeks. Started Nov 2017; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02611167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611167.